Daniel Lebovic, MD
Hematology & Oncology · Langhorne, PANPI 1568645950
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $37,038 of the $51,309 with a category attached, or 72.2%. 60 manufacturers reported payments, led by Johnson & Johnson at 42.5% of the total. Reporting peaked in 2019 at $22,382 and has fallen 51.5% since, to $10,861 in 2025. Among hematology & oncology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 604 payments — averaging $84.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$22K
- Pfizer$10K
- Regeneron Healthcare Solutions, Inc.$8K
- E.r. Squibb & Sons, L.L.C.$2K
- Novartis$1K
- AstraZeneca$894
- plus $7K from 54 others
Across 11 payments — averaging $1806.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$20K
What the payments were for
- Consulting fees$1,6003%
- Speaking & faculty fees$37,03872%
- Travel & lodging$860%
- Food & beverage$12,39124%
- Education$1940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,309 in reported general payments places this provider in the 90th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 21 | $318,842 |
| PomalystPomalidomide | 12 | $289,817 |
| VenclextaVenetoclax | 25 | $262,268 |
| IbrancePalbociclib | 13 | $190,231 |
| XareltoRivaroxaban | 121 | $115,116 |
| EliquisApixaban | 138 | $96,135 |
| Enoxaparin Sodium | 12 | $3,184 |
| Exemestane | 42 | $2,833 |
| Anastrozole | 72 | $1,532 |
| Hydroxyurea | 63 | $1,020 |
| ValacyclovirValacyclovir Hcl | 30 | $957 |
| Dexamethasone | 45 | $783 |
| Warfarin Sodium | 57 | $775 |
| Ondansetron OdtOndansetron | 75 | $769 |
| Oxycodone Hcl | 36 | $617 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $894 | $318,84221 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $1,958 | $289,81712 claims |
| PfizerIbrance, Eliquis | $9,836 | $286,366151 claims |
| AbbVieVenclexta | $498 | $262,26825 claims |
| Johnson & JohnsonXarelto | $21,788 | $115,116121 claims |
| Lilly USA, LLCOlanzapine | $162 | $40018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Langhorne
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
- Charu AggarwalPhiladelphia$541K
- Tracey EvansEast Norriton$500K
- Corey LangerPhiladelphia$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.